Videos
Clinical Conversations by Experts
View all

Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer
- Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6
- Tumor Board Reviewing the Use of PSMA PET in Patient with Gleason 4+5=9, GG 5 Disease, Bone Scan Demonstrated Mild Uptake Prostate Cancer - Session 2 Case 1 - H Jacene, A Kibel, P Nguyen, & A Morgans
- Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 4+5=9, GG 5 with Seminal Vesicle Invasion Prostate Cancer - Session 1 Case 5 - H Jacene, A Kibel, P Nguyen, & A Morgans View all Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer videos

ESMO 2022
- Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints in the VISION Trial - Michael Morris
- Results of Cohort K of the EV-103 Trial EV Monotherapy or in Combination With Pembro in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer - Guru Sonpavde
- Predicting Efficacy of Both Nivolumab and of Nivolumab + Ipilimumab in Frontline mccRCC Patients, An Ancillary Analyses from the BIONIKK Randomized Trial - Maxime Meylan
- Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay View all ESMO 2022 videos

PCF 2022
- Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg
- Disparities in Prostate Cancer: Barriers to Access to Clinical Trials - Elisabeth Heath
- Biological Difference Based on Race: Disparities Throughout the Spectrum of Prostate Cancer - Kosj Yamoah View all PCF 2022 videos
Featured Videos

Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell

The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris

Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
Prostate cancer genomic classifier Videos
Latest Videos
Bladder Cancer Videos

DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt

A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse
Recent Conference Coverage
Conference Highlights Written by Physician-Scientist

Urologists for Social Responsibility 2023 Conference Highlights
- International Perspectives On Setting Up Health Systems
- Physicians Addressing Climate Change
- The University of Michigan Youth Violence Prevention Center
Recent Physician-Scientist Review Articles
State of the Evidence Review Articles

Advanced Prostate Cancer
- Radiotherapy in Prostate Cancer: Utilization in the Metastatic Setting
Written by Christopher J.D. Wallis, MD PhD, Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc
- The Current Landscape of PSMA PET Imaging in Prostate Cancer: Advanced Prostate Cancer
Written by Christopher J.D. Wallis, MD PhD, Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc

mHSPC
- Real-World Utilization of Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer: Are We Lacking Intensity?
Written by Christopher J.D. Wallis, MD PhD, Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc
- The Current Landscape of Metastatic Hormone Sensitive Prostate Cancer: A Plethora of Treatment Options
Written by Zachary Klaassen, MD, MSc, Rashid K. Sayyid, MD, MSc, and Christopher J.D. Wallis, MD, PhD
Transformative Evidence
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Clinical Application And Utility Of PYLARIFY
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
Reno, Nevada (UroToday.com) -- Lantheus Holdings, Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics, and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, showcased artificial intelligence (AI) data at the 2022 European Association of Nuclear Medicine (EANM) Annual Meeting in Barcelona, Spain. Read More
Bladder Cancer Detection
Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.
Reno, Nevada (UroToday.com) -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the commercial availability of Karl Storz’s New Blue Light equipment powered by Saphira™ in the U.S.
As part of the rollout, Karl Storz plans to host a Virtual Launch event for the medical community streamed from its El Segundo, California office where Sia Daneshmand M.D. and Kristin Scarpato M.D. M.P.H. will discuss the clinical benefits of using blue light cystoscopy (BLC®) with Cysview® for NBMIC*,
Read MoreARAMIS Trial
Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Context: Randomized controlled trials (RCTs) have shown that addition of docetaxel or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) or addition of ARAT to ADT and docetaxel improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). However, it is unknown whether docetaxel, when given as part of triplet therapy, has an independent OS benefit. Read More
ARASENS Trial
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown.
Read More
Read More
VISION Trial
FDA Grants Priority Review for Investigational Targeted Radioligand Therapy 177Lu-PSMA-617 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting. Read More